InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 -0.002 (-25%)+
Announcement
Release
30 Apr 2026 8:32AM
Price at Release
$0.006
Full Release
download
Summary
Osteopore Limited's quarterly report for Q1 2026 highlighted a revenue growth of 10% quarter-over-quarter and 4% year-over-year, achieving AUD 754,000. The company secured a multi-year deal with Majeton for the Chinese market worth over RMB 12 million, and expanded its operations in Hong Kong and Singapore with new collaborations and a Centre of Excellence. Key developments include new products for avascular necrosis and precision catheter guides. Financially, Osteopore reported a net cash usage of AUD 205,000 in operations, maintaining a cash balance of AUD 1.734 million, while continuing access to significant funding facilities.
Key Points
  • Osteopore Limited released its quarterly results and Appendix 4C Cash Flow Report for Q1 2026.
  • The company reported a revenue growth of 10% quarter-over-quarter and 4% year-over-year, with a total revenue of AUD 754,000.
  • Osteopore entered a multi-year exclusive collaboration with Majeton in the Chinese market, valued at over RMB 12 million.
  • The company is expanding into Hong Kong with a Global Centre of Excellence and a distribution agreement with MontsMed.
  • Osteopore has developed a new avascular necrosis product in collaboration with Tan Tock Seng Hospital in Singapore.
  • The company is also working on a precision catheter guide with the National University Hospital in Singapore.
  • Osteopore announced its expansion into 3D printing services and distribution rights for a new autologous dentin bone graft technology in Singapore.
  • The company reported a net cash use in operating activities of AUD 205,000, with a cash balance of approximately AUD 1,734,000 as of March 31, 2026.
  • Osteopore maintains access to a redeemable convertible note facility with a nominal value of up to AUD 20 million, with AUD 14.25 million available for future use.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.